Media for culturing stem cells

US9404079B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9404079-B2
Application numberUS-201313909128-A
CountryUS
Kind codeB2
Filing dateJun 4, 2013
Priority dateAug 29, 2005
Publication dateAug 2, 2016
Grant dateAug 2, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of mainataining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of expanding and maintaining human pluripotent stem cells in an undifferentiated state, the method comprising culturing the human pluripotent stem cells in a culture medium comprising a transforming growth factor beta 3 (TGFβ3) isoform— and factors that maintain and expand human pluripotent stem cells in an undifferentiated state, thereby expanding and maintaining the human pluripotent stem cells in the undifferentiated state. 2. The method of claim 1 , wherein said human pluripotent stem cells are human embryonic stem cells. 3. The method of claim 1 , wherein the human pluripotent stem cells are cultured in suspension. 4. The method of claim 1 , wherein the human pluripotent stem cells are cultured on a feeder-layer free matrix. 5. The method of claim 4 , wherein said feeder-layer free matrix is a fibronectin matrix. 6. The method of claim 1 , wherein the human pluripotent stem cells are cultured on feeder cells. 7. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 0.5 ng/ml. 8. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 2 ng/ml. 9. The method of claim 1 , wherein said culture medium further comprises basic fibroblast growth factor (bFGF). 10. The method of claim 9 , wherein said bFGF is provided at a concentration of at least 2 ng/ml. 11. The method of claim 1 , wherein said culture medium is serum-free. 12. The method of claim 1 , wherein said culture medium is devoid of animal contaminant. 13. The method of claim 3 , wherein said suspension is protein carrier-free.

Assignees

Inventors

Classifications

  • Xeno-free medium · CPC title

  • Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies · CPC title

  • Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

  • Vertebrate cells · CPC title

  • C12N5/0606Primary

    Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9404079B2 cover?
Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of mainataining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and derivin…
Who is the assignee on this patent?
Technion Res & Dev Foundation
What technology area does this patent fall under?
Primary CPC classification C12N5/0606. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).